866-997-4948(US-Canada Toll Free)

Oropharyngeal Cancer-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Oct 2017

Category :

Pharmaceutical

No. of Pages : 241 Pages

Oropharyngeal Cancer-Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Oropharyngeal Cancer-Pipeline Review, H2 2017, provides an overview of the Oropharyngeal Cancer (Oncology) pipeline landscape.

Oropharyngeal cancer is a disease which malignant cells form in the tissue of oropharynx. Oropharynx is a middle part of the throat which includes the base of the tongue, the tonsils, the soft palate, and the walls of the pharynx. Oropharyngeal cancers can be divided into two types, HPV-positive, which are related to human papillomavirus infection, and HPV-negative cancers, which are usually linked to alcohol or tobacco use.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Oropharyngeal Cancer-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Oropharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oropharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oropharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0 and Preclinical stages are 1, 5, 9, 1 and 4 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Oropharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Oropharyngeal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Oropharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Oropharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Oropharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Oropharyngeal Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Oropharyngeal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Oropharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Oropharyngeal Cancer-Overview 6
Oropharyngeal Cancer-Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 12
Oropharyngeal Cancer-Therapeutics Assessment 13
Assessment by Target 13
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Oropharyngeal Cancer-Companies Involved in Therapeutics Development 21
Advaxis Inc 21
Astex Pharmaceuticals Inc 21
AstraZeneca Plc 21
Celldex Therapeutics Inc 22
Immunovaccine Inc 22
Incyte Corp 23
ISA Pharmaceuticals BV 23
Madrigal Pharmaceuticals Inc. 24
MedImmune LLC 24
Merck & Co Inc 25
Merck KGaA 25
Pfizer Inc 26
PNP Therapeutics Inc 26
Tessa Therapeutics Pte Ltd 27
Theralase Technologies Inc 27
Transgene SA 28
Oropharyngeal Cancer-Drug Profiles 29
avelumab-Drug Profile 29
axalimogene filolisbac-Drug Profile 42
BMX-001-Drug Profile 61
CDX-3379-Drug Profile 63
DPXE-7-Drug Profile 67
durvalumab-Drug Profile 69
durvalumab + tremelimumab-Drug Profile 88
ganetespib-Drug Profile 95
gedatolisib-Drug Profile 108
gedeptin-Drug Profile 110
ISA-101-Drug Profile 112
nimotuzumab-Drug Profile 117
olaparib-Drug Profile 122
onalespib-Drug Profile 135
pembrolizumab-Drug Profile 139
PGV-001-Drug Profile 207
ruxolitinib phosphate-Drug Profile 208
TG-4001-Drug Profile 223
TLD-1433-Drug Profile 225
TT-12-Drug Profile 228
utomilumab-Drug Profile 229
Oropharyngeal Cancer-Dormant Projects 232
Oropharyngeal Cancer-Discontinued Products 233
Oropharyngeal Cancer-Product Development Milestones 234
Featured News & Press Releases 234
Appendix 239
Methodology 239
Coverage 239
Secondary Research 239
Primary Research 239
Expert Panel Validation 239
Contact Us 239
Disclaimer 240

List of Tables
Number of Products under Development for Oropharyngeal Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Oropharyngeal Cancer-Pipeline by Advaxis Inc, H2 2017
Oropharyngeal Cancer-Pipeline by Astex Pharmaceuticals Inc, H2 2017
Oropharyngeal Cancer-Pipeline by AstraZeneca Plc, H2 2017
Oropharyngeal Cancer-Pipeline by Celldex Therapeutics Inc, H2 2017
Oropharyngeal Cancer-Pipeline by Immunovaccine Inc, H2 2017
Oropharyngeal Cancer-Pipeline by Incyte Corp, H2 2017
Oropharyngeal Cancer-Pipeline by ISA Pharmaceuticals BV, H2 2017
Oropharyngeal Cancer-Pipeline by Madrigal Pharmaceuticals Inc., H2 2017
Oropharyngeal Cancer-Pipeline by MedImmune LLC, H2 2017
Oropharyngeal Cancer-Pipeline by Merck & Co Inc, H2 2017
Oropharyngeal Cancer-Pipeline by Merck KGaA, H2 2017
Oropharyngeal Cancer-Pipeline by Pfizer Inc, H2 2017
Oropharyngeal Cancer-Pipeline by PNP Therapeutics Inc, H2 2017
Oropharyngeal Cancer-Pipeline by Tessa Therapeutics Pte Ltd, H2 2017
Oropharyngeal Cancer-Pipeline by Theralase Technologies Inc, H2 2017
Oropharyngeal Cancer-Pipeline by Transgene SA, H2 2017
Oropharyngeal Cancer-Dormant Projects, H2 2017
Oropharyngeal Cancer-Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Oropharyngeal Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *